Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration

被引：95

作者：

Feeley, Brian T.

Liu, Nancy Q.

Conduah, Augustine H.

Krenek, Lucie

Roth, Kevin

Dougall, William C.

Huard, Johnny

Dubinett, Steve

Lieberman, Jay R.

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed Surg, Ctr Hlth Sci, Los Angeles, CA 90095 USA

[2] Amgen Inc, Seattle, WA USA

[3] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA

[4] Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA

[5] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2006年 / 21卷 / 10期

关键词：

RANK; RANK ligand; RANK : Fc protein; osteoclastogenesis; bone metastasis; noggin;

D O I：

10.1359/JBMR.060706

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lung cancer metastases to bone produce a primarily mixed osteolytic/osteoblastic lesion. The purpose of this study was to determine if blockade of both pathways would inhibit the formation these lesions in bone. Inhibition of the osteoblastic lesion with noggin and the osteolytic lesion with RANK:Fc was a successful treatment strategy to inhibit progression of mixed lung cancer lesions in bone.

引用

页码：1571 / 1580

页数：10

共 53 条

[1]

Angelucci A, 2004, INT J ONCOL, V25, P1713

[2] Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: Importance of BMP2 [J].

Arnold, SF ;

Tims, E ;

McGrath, BE .

CYTOKINE, 1999, 11 (12) :1031-1037

[3] Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway [J].

Bendre, MS ;

Margulies, AG ;

Walser, B ;

Akel, NS ;

Bhattacharrya, S ;

Skinner, RA ;

Swain, F ;

Ramani, V ;

Mohammad, KS ;

Wessner, LL ;

Martinez, A ;

Guise, TA ;

Chirgwin, JM ;

Gaddy, D ;

Suva, LJ .

CANCER RESEARCH, 2005, 65 (23) :11001-11009

[4]

Brown Julie M, 2004, Cancer Treat Res, V118, P149

[5] In vivo RANK signaling blockade using the receptor activator of NF-κB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis [J].

Childs, LM ;

Paschalis, EP ;

Xing, LP ;

Dougall, WC ;

Anderson, D ;

Boskey, AL ;

Puzas, JE ;

Rosier, RN ;

O'Keefe, RJ ;

Boyce, BF ;

Schwarz, EM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (02) :192-199

[6] Osteoprotegerin in prostate cancer bone metastasis [J].

Corey, E ;

Brown, LG ;

Kiefer, JA ;

Quinn, JE ;

Pitts, TEM ;

Blair, JM ;

Vessella, RL .

CANCER RESEARCH, 2005, 65 (05) :1710-1718

[7] Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein [J].

Dai, JL ;

Kitagawa, Y ;

Zhang, J ;

Yao, Z ;

Mizokami, A ;

Cheng, SY ;

Nör, J ;

McCauley, LK ;

Taichman, RS ;

Keller, ET .

CANCER RESEARCH, 2004, 64 (03) :994-999

[8]

Doherty A, 1999, J PATHOL, V188, P278, DOI 10.1002/(SICI)1096-9896(199907)188:3<278::AID-PATH358>3.0.CO

[9]

2-G

[10] Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer [J].

Feeley, BT ;

Gamradt, SC ;

Hsu, WK ;

Liu, N ;

Krenek, L ;

Robbins, P ;

Huard, J ;

Lieberman, JR .

JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (12) :2189-2199

← 1 2 3 4 5 6 →